Lipoprotein(a) and oxygen free radicals in survivors of acute myocardial infarction: Effects of captopril

Cardiology (Switzerland)

Volumn 87, Issue 1, 1996, Pages 18-22

  Sogaard, Peter ^a   Klausen, Lb Christian ^a   Rungby, Jorgen ^a   Faergeman, Ole ^a   Thygesen, Kristian ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Captopril; Lipoprotein(a); Myocardial infarction; Oxygen free radicals

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPOPROTEIN A; MALONALDEHYDE; OXYGEN RADICAL; SCAVENGER;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0029655249     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000177054     Document Type: Article

References (27)

1. Sandkamp M. Funke H, Schulze H. Kohler H. Assmann G: Lipoprotein(a) is an independent factor for myocardial infarction at a young age. Clin Chem 1990;36:20-23.
2. Molgaard J. Klausen IC. Lassvik C. Faergeman O. Gerdes LU. Olsson AG: Significant association between low molecular weight apolipopro-tein(a) isoforms and intermittent claudication. Atheroscler Thromb 1992; 12:895-901.
3. Dahlen G. Guyton JR. Attar M, Farmer JA, Kaulz JA, Gotto AM Jr: Association of levels of lipoprotein(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986:74: 758-765.
4. Kroon AA. Demacker PNM. Stalenhoef FIL N-acetylcysteine and serum concentrations of lipoprotcin(a). J Intern Med 1991:230:519-526.
5. Gavish D. Breslow JL: Lipoprotein(a) reduction by N-acctylcysteine. Lancet 1991:337: 203-204.
6. McCord JM: Oxygen-derived free radicals in post ischemic tissue injury. N Engl J Med 1985: 312:59-63.
7. Belch JJF. Bridges AB. Scott N. Chopra M: Oxygen free radicals and congestive heart failure. Br Heart J 1991:65:245-248.
8. Freeman BA. Crapo JD: Biology of disease: Free radicals and tissue injury. Lab Invest 1982:47:412-426.
9. Meerson FZ. Kagon VE, Kozlov YP: The role of lipid peroxidation in pathogenesis of ischemic damage and antioxidant protection of the heart. Basic Res Cardiol 1982:77:465-485.
10. Prasad K. Kalra J: Oxygen free radicals and hypcrcholesterolemic atherosclerosis: Effect of vitamin E. Am Heart J 1993:125:958-973.
11. Sogaard P. Norgaard A. Gotzschc C-O. Rav-kilde J.Thygesen K: Therapeutic effects of cap-topril on ischemia and dysfunction of the left ventricle after Q-wave and non Q-wave myocardial infarction. Am Heart J 1994:127:1-7.
12. World Health Organization: Report of the Fifth Working Group on the Establishment of Ischemic Heart Disease Registers. Copenhagen. WHO Regional Office for Europe. 1971.
13. Klausen IC. Gerdes LU. Schmidt F.B, Dverberg J. Faergeman O: Differences in apolipopro-tein(a) polymorphism in west Greenland Eski-rnoes and Caucasian Danes. Hum Genet 1992; 89:384-388.
14. Kraft HG. Dieplinger H. Hoye E, Utermann G: Lp(a)phenolypingby immunoblottingwith polyclonal and monoclonal antibodies. Atherosclerosis 1988;8:212-216.
15. Utermann G. Menzel HJ. Kraft HG. Duba IIC, Kemmler HG, Seitz C: Lp(a) glycoprotein phenotypes: Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987;80:458-465.
16. Sandholzer C. Saha N. Kark JD, Rees A, Jaross W. Dieplinger H. Hoppichler F. Boerwinkle E, Utermann G: Apo(a) isoforms predicts risk for coronary heart disease: A study of six populations. Arteriosclerosis Thromb 1992:12:1214-1226.
17. Rungby J. First E: Experimentally induced lipid peroxidation after exposure to chromium, mercury or silver: Interaction with carbon tetrachloride. Pharmacol Toxicol 1992:70:205-207.
18. Armstrong VW, Walli AK. Seidel D. Isolation, characterization and uptake in human fibroblasts of an apo(a)-frec lipoprotein obtained on reduction of lipoprotein(a). J Lipid Res 1985: 26:1314-1323.
19. Sonodo M, Sakamoto K, Miyauchi T. Sanada J, Nakamura K. Arinta T. Kuriyama M, Naga-ta K. Osame M. Miyahara K: Changes in serum lipoprotein(a) and C4B binding protein levels alter acute myocardial infarction. Jpn Circ J 1992:56:1214-1220.
20. Tarkowski A, Carlstcn II, Herlitz H. Westberg G: Differential effects of captopril and cncla-pril. Two angiotensin converting enzyme inhibitors, cn the immune reactivity in experimental lupus disease. Agents Actions 1990:31:96-101.
21. Klausen IC. Schmidt EB. lervang IIII, Gerdes LU. Ditzel J. Faergeman O: Normal lipoprotei-n(a) concentrations and apolipoprotein(a) isoforms in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest 1992:22:538-541.
22. Molitemo DJ, Lange RA, Meidcll RS. Willard JE, Leffert CC, Gerard RD. Boerwinkle E. Hobbs HH, Hillis LD: Relation of plasma lipo-protein(a) to infarct artery patency in survivors of myocardial infarction. Circulation 1993:88: 935-940.
23. Chobanian AV. Haudenschild CC, Nickerson C, Drago R: Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidémie rabbit. Hypertension 1990;15:327-331.
24. Webb RC. Finta KM. Fisher M: Ramipril reverses impaired endothelium-dependent relaxation in arteries from rabbit fed an atherogenic diet. FASEB J 1992;6:A 1458.
25. Chobanian AV: The effect of ACE-inhibilors and other antihypertensive drugs on cardiovascular risk factors and atherogenesis. Clin Cardiol 1990:13:743-48.
26. Chopra M. McMurrav J, McLay J. Bridges A, Scott N. Smith WE, Belch JJ: Oxidative damage in chronic heart failure: Protection by cap-lopril through free radical scavenging. Adv Exp Med Biol 1990:264:251-255.
27. Pfeffer MA. Braunwald E. Moye LA. Basta L, Brown EJ Jr. Cuddy TE. Davis BR. Geltman FM. Goldman S. Fiaker GC. Klein M. Lamas GA. Packer M. Rouleau J. Rouleau JL. Rutherford J. Wertheimer JH, Hawkins CM: Effects of captopril on mortality and morbidity in patients with left-ventricular dysfunction after myocardial infarction. N Engl J Med 1992:327: 669-677.